These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 21503644)

  • 1. Safety and clinical efficacy of platelet components prepared with pathogen inactivation in routine use for thrombocytopenic patients.
    Schlenke P; Hagenah W; Irsch J; Sundin D; Corash L; Lin L; Kirchner H; Wagner T
    Ann Hematol; 2011 Dec; 90(12):1457-65. PubMed ID: 21503644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction.
    Kerkhoffs JL; van Putten WL; Novotny VM; Te Boekhorst PA; Schipperus MR; Zwaginga JJ; van Pampus LC; de Greef GE; Luten M; Huijgens PC; Brand A; van Rhenen DJ;
    Br J Haematol; 2010 Jul; 150(2):209-17. PubMed ID: 20507310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogen-inactivation of platelet components with the INTERCEPT Blood System ™: a cohort study.
    Infanti L; Stebler C; Job S; Ruesch M; Gratwohl A; Irsch J; Lin L; Buser A
    Transfus Apher Sci; 2011 Oct; 45(2):175-81. PubMed ID: 21840762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion.
    Lozano M; Knutson F; Tardivel R; Cid J; Maymó RM; Löf H; Roddie H; Pelly J; Docherty A; Sherman C; Lin L; Propst M; Corash L; Prowse C
    Br J Haematol; 2011 May; 153(3):393-401. PubMed ID: 21418180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment.
    Osselaer JC; Messe N; Hervig T; Bueno J; Castro E; Espinosa A; Accorsi P; Junge K; Jacquet M; Flament J; Corash L
    Transfusion; 2008 Jun; 48(6):1061-71. PubMed ID: 18346019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial.
    Snyder E; McCullough J; Slichter SJ; Strauss RG; Lopez-Plaza I; Lin JS; Corash L; Conlan MG;
    Transfusion; 2005 Dec; 45(12):1864-75. PubMed ID: 16371039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment.
    Osselaer JC; Cazenave JP; Lambermont M; Garraud O; Hidajat M; Barbolla L; Tardivel R; Defoin L; Waller C; Mendel I; Raidot JP; Kandel G; De Meuter R; Fabrigli P; Dehenau D; Arroyo JL; Padrón F; Gouezec H; Corral M; Jacquet M; Sundin D; Lin L; Corash L
    Vox Sang; 2008 May; 94(4):315-23. PubMed ID: 18248574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effect of buffy-coat vs. apheresis platelet concentrates in patients with severe thrombocytopenia after intensive chemotherapy.
    Akkök CA; Brinch L; Lauritzsen GF; Solheim BG; Kjeldsen-Kragh J
    Vox Sang; 2007 Jul; 93(1):42-8. PubMed ID: 17547564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot study.
    Simonsen AC; Johansson PI; Conlan MG; Jacquet M; Lin JS; Junge K; Lin L; Sørensen H; Borregaard N; Flament J
    Transfusion; 2006 Mar; 46(3):424-33. PubMed ID: 16533286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia.
    Slichter SJ; Raife TJ; Davis K; Rheinschmidt M; Buchholz DH; Corash L; Conlan MG
    Transfusion; 2006 May; 46(5):731-40. PubMed ID: 16686840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.
    Vadhan-Raj S; Kavanagh JJ; Freedman RS; Folloder J; Currie LM; Bueso-Ramos C; Verschraegen CF; Narvios AB; Connor J; Hoots WK; Broemeling LD; Lichtiger B
    Lancet; 2002 Jun; 359(9324):2145-52. PubMed ID: 12090979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Réunion.
    Rasonglès P; Angelini-Tibert MF; Simon P; Currie C; Isola H; Kientz D; Slaedts M; Jacquet M; Sundin D; Lin L; Corash L; Cazenave JP
    Transfusion; 2009 Jun; 49(6):1083-91. PubMed ID: 19309473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The efficacy and safety of autologous cryopreserved platelet transfusion in management of thrombocytopenia after chemotherapy in hematological malignancy].
    Liu GQ; Ding HF; Lu XJ; Xu M; Xing J; Zhao X; Han F; Shang YH
    Zhonghua Nei Ke Za Zhi; 2012 Mar; 51(3):188-91. PubMed ID: 22781890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment.
    Cazenave JP; Waller C; Kientz D; Mendel I; Lin L; Jacquet M; Propst M; Liu W; Corash L; Sundin D; Defoin L; Messe N; Osselaer JC
    Transfusion; 2010 Jun; 50(6):1210-9. PubMed ID: 20113450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set.
    Janetzko K; Cazenave JP; Klüter H; Kientz D; Michel M; Beris P; Lioure B; Hastka J; Marblie S; Mayaudon V; Lin L; Lin JS; Conlan MG; Flament J
    Transfusion; 2005 Sep; 45(9):1443-52. PubMed ID: 16131376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of platelet function using the in vitro bleeding time and corrected count increment of transfused platelets. Comparison between platelet concentrates derived from pooled buffy coates and apheresis.
    Eriksson L; Kristensen J; Olsson K; Bring J; Högman CF
    Vox Sang; 1996; 70(2):69-75. PubMed ID: 8801766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic efficacy of pooled buffy-coat platelet components prepared and stored with a platelet additive solution.
    van Rhenen DJ; Gulliksson H; Cazenave JP; Pamphilon D; Davis K; Flament J; Corash L
    Transfus Med; 2004 Aug; 14(4):289-95. PubMed ID: 15285725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of transfusion of platelet concentrates obtained by manual pooling or by semiautomated pooling of buffy-coats: a retrospective analysis of count increment, corrected count increment and transfusion interval.
    Cid J; Ramiro L; Escoda L; Llorente A
    Vox Sang; 2009 Jan; 96(1):29-33. PubMed ID: 19121195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogen inactivation of platelets with a photochemical treatment with amotosalen HCl and ultraviolet light: process used in the SPRINT trial.
    Pineda A; McCullough J; Benjamin RJ; Cable R; Strauss RG; Burgstaler E; Porter S; Lin L; Metzel P; Conlan MG;
    Transfusion; 2006 Apr; 46(4):562-71. PubMed ID: 16584432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pooled platelet concentrates: an alternative to single donor apheresis platelets?
    Pietersz RN
    Transfus Apher Sci; 2009 Oct; 41(2):115-9. PubMed ID: 19716340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.